Analysis of Aminoglycosides Market
Aminoglycosides
Monosulfate kanamycin, the price is stable with a slight downward trend, the market price is 305, the actual transaction price is negotiable, up 3.38% year-on-year
Neomycin sulfate, the market is running smoothly, the transaction price is 147-155, which is the same as the price of the previous month, up 6.5% year-on-year, and the current market supply is sufficient, and it may remain stable in the short term
Spectinomycin hydrochloride, the market demand is reduced, the price is weak, 540-550
Gentamicin sulfate, the price fluctuates and adjusts upward, the market demand is limited, the quotation is 1530
Streptomycin sulfate, with limited production capacity, tight supply, and relatively stable prices at high levels 265-285
Apramycin sulfate, the price is stable, the market transaction is flat, and the market price is around 207. In the first half of 2019, the price was above 300. After the second half of 2019, the price dropped to less than 300. Since then, the average price has declined year by year. The lowest price in 2020 is around 225 in November, and the highest price in 2021 is around 280 in April, and then gradually The current price has dropped to a new low in the past five years. At present, due to the impact of demand and the new version of GMP on production, it may remain low in the short term, but whether it can become an inflection point, we will continue to pay attention to it.
Looking for chemical products? Let suppliers reach out to you!
2026-06-26
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Week 21 Partial Veterinary Drug Quotes 2
-
Analysis of The Domestic Veterinary Drug Raw Material Market In The Seventh Week of 2022-1
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
BASF Raises API and Excipient Prices
-
IPEC Updates Excipient Qualification Guidance
-
Pharmaceutical Tariffs Put Ingredients Back in Focus
-
West Asia Tensions Squeeze Pharma Raw Materials
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
Recommend Reading
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
Roche Keeps German Diagnostics Investment
-
Formic Acid Shows a Stalemate Trend of "Stable Prices and Flat Volumes"
-
Raw Material Expectations Weak, ABS Market Shakes and Turns Down
-
Supply and Demand Loosening—Shandong Cyclohexanone Market Operates Weakly After the Holiday
-
In March, the Chinese marine fuel market saw a significant increase
-
Asia’s Plastics Chain Faces a Shock: Tight Naphtha Supply Drives Up Polymer Costs